^
    Back
    Association details:
    Biomarker:PD-1 expression
    Cancer:Merkel Cell Carcinoma
    Drug Class:Immunotherapy
    Direction:Sensitive
    Evidence:
    Evidence Level:
    Sensitive: C3 – Early Trials
    New
    Source:
    Clin Cancer Res
    Title:

    The Genomic Landscape of Merkel Cell Carcinoma and Clinicogenomic Biomarkers of Response to Immune Checkpoint Inhibitor Therapy

    Published date:
    08/09/2019
    Excerpt:
    "Comprehensive molecular profiling was performed on 317 tumors from patients with MCC... there was a statistically significant association between PD-1 status and response rate, with 10 of 13 (77%) of patients with PD-1 positive tumors responding compared with 3 of 14 (21%) of PD-1 negative (P ¼ 0.00598)."
    DOI:
    10.1158/1078-0432.CCR-18-4159